Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Humanigen Takes Aim At IL-6 Inhibitors With CRS Drug Lenzilumab

Company Targets COVID-19, CAR-T, GvHD Markets

Executive Summary

Roche's Actemra is a major player in this space, but Humanigen is looking to take it on directly.

You may also be interested in...



Humanigen Raises Chances of Lenzilumab EUA With Severe COVID-19 Data

Data on medRxiv showed a 90% improvement in likelihood of need for mechanical ventilation in the intent-to-treat population. The company plans a filing in Q2.

GSK Antibody Appears Effective In Older COVID-19 Patients

With elderly patients disproportionately facing hospitalization and death from COVID-19, success in the clinic would create an important market for the drug.

Coronavirus Update: EU Demands AstraZeneca Meets Its Vaccines Commitments After Supply Warning

Plus Takeda starts vaccine trial in Japan and South Korea clears Celltrion's antibody therapeutic. 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC143666

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel